IP Library › Granted Patent US 12,303,477
Granted Patent B2
US 12,303,477 · App. 18/452,167 · Granted May 20, 2025

HIV treatment compositions and methods

Inventors: Kayvan Niazi (Culver City, CA); Jeffrey Safrit (Culver City, CA); John H. Lee (Culver City, CA)
Assignees: NantCell, Inc.; NantKwest, Inc.
A61K31/167A61K31/192A61K31/215A61K31/4045A61K31/4406A61K31/506A61K38/2086A61K39/12A61K40/11A61K40/15A61K40/31A61K40/46C07K14/70535C07K16/1003C07K16/1063
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,303,477
App. No.
18/452,167
Granted
May 20, 2025
Kind
B2
Abstract

HIV treatment, and especially treatment of latent infected CD4 cells, can be significantly improved using a kick-and-kill approach that employs an immune stimulation component and/or HDAC inhibition as one treatment component, and that may also include a second component in which a vaccine composition, various NK cells, CAR-T cells, and/or broadly neutralizing antibodies are administered.

Claims (15)

1. A method of treating an individual that carries latent human immunodeficiency virus (HIV) infected cells, the method comprising:

administering to the individual IL-15 or an enhanced immune stimulatory derivative thereof, and a broadly neutralizing anti-HIV antibody (bNAb).

2. The method of claim 1 , further comprising administering a histone deacetylase (HDAC) inhibitor.

3. The method of claim 2 , wherein the HDAC inhibitor is vorinostat, panobinostat, valproic acid, phenylbutyrate, entinostat, CI-994, mocetinostat, Viracta 3996, dacinostat, pivanex, givinostat, or belinostat.

4. The method of claim 2 , wherein the HDAC inhibitor is administered at least 24 hours before or after the IL-15, or the enhanced immune stimulatory derivative thereof.

5. The method of claim 1 , wherein a natural killer cell that is genetically modified to express a high affinity CD16 receptor is also administered to the individual.

6. The method of claim 5 , wherein the natural killer cell is an autologous NK cell, an NK92 cell, an aNK cell, a haNK cell, or a taNK cell.

7. The method of claim 1 , wherein a vaccine composition is also administered to the individual, and wherein the vaccine composition is a bacterial vaccine, a yeast vaccine, or a viral vaccine, and further wherein the vaccine composition comprises a recombinant nucleic acid that encodes at least one HIV antigen.

8. The method of claim 7 , wherein the yeast vaccine is a Saccharomyces cerevisiae vaccine.

9. The method of claim 7 , wherein the viral vaccine is an adenoviral vaccine.

10. The method of claim 1 , further comprising administering a CAR-T cell that has a chimeric antigen receptor (CAR) with an ectodomain that binds to CD2, CD20, or CD32.

11. The method of claim 1 , wherein the bNAb is selected from the group consisting of PGT121, 10-1074, 10E8, 10E8v4-V5R-100cF, 2F5, 2G12, 3BNC117, CAP256, VRC26,25, N6, PG9, PGDM1400, VRC01, and VRC07-523.

12. The method of claim 7 , wherein the individual is administered two or more of the vaccine compositions.

13. The method of claim 12 , wherein the individual is administered three or more of the vaccine compositions.

14. The method of claim 1 , wherein the enhanced immune stimulatory derivative of IL-15 comprises a TxM.

Assignments (4)
SECURITY INTEREST Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
NUNC PRO TUNC ASSIGNMENT Recorded Aug 18, 2023
From: LEE, JOHN H.; SAFRIT, JEFFREY
To: NANTKWEST, INC.
Reel/Frame 064637/0091 →
NUNC PRO TUNC ASSIGNMENT Recorded Aug 18, 2023
From: NIAZI, KAYVAN
To: NANTBIO, INC.
Reel/Frame 064637/0164 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2023
From: NANTBIO, INC.
To: NANTCELL, INC.
Reel/Frame 064637/0315 →
Continuity (4)
Continuation 17475783 · Sep 15, 2021
Continuation 16443560 · Jun 17, 2019
Provisional Application 62686846 · Jun 19, 2018
Related Publication 20230398186A1 · Dec 14, 2023
References Cited (51)
US 10047146B2 · Mouquet et al. · 2018 [cited by applicant]
US 20150183835A1 · Carfi et al. · 2015 [cited by applicant]
CN 107249602A · 2017 [cited by applicant]
CN 108174604A · 2018 [cited by applicant]
WO 2008097863A2 · 2008 [cited by applicant]
WO 2010067980A2 · 2010 [cited by applicant]
WO 2013163427A1 · 2013 [cited by applicant]
WO 2013165592A1 · 2013 [cited by applicant]
WO 2016063251A1 · 2016 [cited by applicant]
WO 2016154003A1 · 2016 [cited by applicant]
WO 2017106346A2 · 2017 [cited by applicant]
WO 2017222619A2 · 2017 [cited by applicant]
WO 2018013975A1 · 2018 [cited by applicant]
WO 2018022358A1 · 2018 [cited by applicant]
WO 2018075989A1 · 2018 [cited by applicant]
WO 2019245993A1 · 2019 [cited by applicant]
Davis et al., “A Phase 1 Study of ALT-803 (IL-15 Superagonist) to Clear Latent HIV Reservoirs”, Poster # 356, p. 1. [cited by applicant]
Webb et al., “The human IL-15 superagonist ALT-803 directs SIV-specific CD8+ T cells into B-cell follicles”, Blood Advances, vol. 2, No. 2, Jan. 23, 2018, pp. 9. [cited by applicant]
Iglesias-Ussel et al., “High Levels of CD2 Expression Identify HIV-1 Latently Infected Resting Memory CD4+ T Cells in Virally Suppressed Subjects”, Journal of Virology, vol. 87, No. 6, Aug. 2013, pp. 9148-9158. [cited by applicant]
Jones, et al., “A subset of latency-reversing agents 1,2,4,33-37 expose HIV-infected resting CD4+ T-cells to recognition by cytotoxic T-lymphocytes”, PLOS Pathogens, 2016, vol. 12, No. 4, e1005545, pp. 1-25. [cited by applicant]
Sengupta et al., “Targeting the latent reservoir for HIV-1”, Immunity, May 2018, vol. 48, pp. 872-895. [cited by applicant]
Garrido et al., “Inlerleukin-15-slimulaled natural killer cells clear HIV-1-infecled cells following latency reversal Ex Vivo” , Journal of Virology, May 29, 2018, vol. 92, issue 12, e00235-18, pp. 1-13. [cited by applicant]
International Search Report and Written Opinion received for PCT Application Serial No. PCT/US2019/037537 dated Oct. 18, 2019, 12 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Application Serial No. PCT/US2019/037537 dated Feb. 16, 2021, 16 pages. [cited by applicant]
Zeligs et al., “Preclinical characterization of a novel monoclonal antibody targeting a neo-antigen expressed in ovarian and GI malignancies”, Cancer Res, 2017, Abstract 3025, vol. 77, Issue 13_Supplement, 2 pages. [cited by applicant]
Xu et al., “Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor α/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma”, Cancer Res. May 15, 2013; 73(10): 3075-30… [cited by applicant]
Fantini et al., “Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas”, Frontiers in Immunology, 2018, vol. 8, Article 1899, 14 pages. [cited by applicant]
Conlon et al., “Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With C… [cited by applicant]
Rosario et al., “The IL-15 superagonist ALT-803 enhances anti-CD20 antibody-directed NK cell ADCC and in vivo clearance of B cell lymphomas”, Journal for Immuno Therapy of Cancer, 2014, 2 (Suppl 3):P168. [cited by applicant]
Jen Hodson, “Precision Biologics to Highlight Preclinical Data on NEO-201, a Neoantigen Targeting Antibody in Oral Presentation at the 110th Annual Meeting of the American Association of Clinical Research”, Precision Bi… [cited by applicant]
Ferrari et al., “Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection”, The Journal of Infectious Diseases, 2017, vol. 215, pp. S152-S159. [cited by applicant]
Bruel et al., “Elimination of HIV-1-infected cells by broadly neutralizing antibodies”, Nature Communications, 2016, vol. 7, No. 10844, pp. 1-12. [cited by applicant]
Kramski et al., “HIV-specific Antibody Immunity Mediated Through NK Cells and Monocytes”, Current HIV Research, 2013, vol. 11, pp. 388-406. [cited by applicant]
Amalfitano et al., “Production and Characterization of Improved Adenovirus Vectors with the E1, E2b, and E3 Genes Deleted”, Journal of Virology, Feb. 1998, vol. 72, No. 2, pp. 926-933. [cited by applicant]
First Office Action received for Taiwanese Patent Application Serial No. 108121164 dated Mar. 24, 2020, 10 pages (including English Translation). [cited by applicant]
Office Action received for Taiwanese Patent Application Serial No. 108121164 dated Sep. 29, 2020, 16 pages (Including English Translation). [cited by applicant]
Communication pursuant to Rule 164(1) EPC received for European Patent Application Serial No. 19823605.1 dated Jul. 29, 2021, 18 pages. [cited by applicant]
“A Phase 1 Study of ALT-803 (IL-15 Superagonist) to Clear Latent HIV Reservoirs”, Conference on Retroviruses and Opportunistic Infections (CROI), Novel Interventions To Target HIV Reservoirs, 2018, Abstract 356, Session… [cited by applicant]
Seay et al., “In Vivo Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized Mice”, Journal of Virology, 2015, vol. 89, No. 12, pp. 626… [cited by applicant]
Halper-Stromberg et al., “Broadly Neutralizing Antibodies and Viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice”, Cell, 2014, vol. 158, No. 5, pp. 989-999. [cited by applicant]
Extended European Search Report received for European Patent Application Serial No. 19823605.1 dated Nov. 3, 2021, 15 pages. [cited by applicant]
First Examination Report received for CA Patent Application Serial No. 3100282 dated Feb. 16, 2022, 03 pages. [cited by applicant]
Bardhi, et al., “Potent in vivo NK cellmediated elimination of HIV-1-infected cells mobilized by a gp120-bispecific and hexavalent broadly neutralizing fusion protein”, Journal of virology, 2017, vol. 91, issue 20, e009… [cited by applicant]
Office Action received for Taiwanese Patent Application Serial No. 108121164 dated Jun. 22, 2022, 15 pages (Including English Translation). [cited by applicant]
Ren, et al., “Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B Hiv Reactivated from Latent Reservoirs”, Journal of Virology, 2018… [cited by applicant]
Office Action received for Taiwanese Patent Application Serial No. 108121164 dated Sep. 26, 2022, 04 pages (Including English Translation). [cited by applicant]
First Office Action received for CN Application No. 201980041446.X dated Jun. 3, 2023, 25 pages (Including English Translation). [cited by applicant]
Second Examination Report received for CA Patent Application Serial No. 3100282 dated Nov. 23, 2022, 04 pages. [cited by applicant]
Notice of Allowance received for CA Patent Application Serial No. 3100282 dated Jul. 12, 2023, 01 page. [cited by applicant]
Examination Report received for CA Patent Application Serial No. 3100282 dated Sep. 13, 2023, 03 pages. [cited by applicant]
Xu et al., “Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques”, Science, vol. 358, No. 6359, 2017, 13 pages. [cited by applicant]